Evidence map›Paper›PMID 38918239›Full record

ArticlePediatric cardiology2025

Establishing Optimal Control Cohorts for Phase 1 Trials: Retrospective Analysis of Clinical and Biological Outcomes in Neonates and Infants Undergoing Two-Ventricle Repair.

Kumi Kobayashi, Kei Kobayashi, Christopher Liu, Julia Ryan, David Zurakowski, Nobuyuki Ishibashi

Abstract read
In one paragraph

Article in Pediatric cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kumi Kobayashi *Center for Neuroscience Research and Sheikh Zayed Institute for Pediatric Surgical Innovation, Children's National Hospital, Washington, DC, USA.
Kei Kobayashi *Center for Neuroscience Research and Sheikh Zayed Institute for Pediatric Surgical Innovation, Children's National Hospital, Washington, DC, USA.
Christopher LiuVirginia Commonwealth University School of Medicine, Richmond, VA, USA.
Julia RyanThe George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
David ZurakowskiDepartments of Anesthesiology and Surgery, Harvard Medical School, Boston Children's Hospital, Boston, MA, USA.
Nobuyuki IshibashiCenter for Neuroscience Research and Sheikh Zayed Institute for Pediatric Surgical Innovation, Children's National Hospital, Washington, DC, USA. nishibas@childrensnational.org.

Funding

Cell Therapy for Neuroprotection in Congenital Heart DiseaseR01HL139712 · NHLBI · CHILDREN'S RESEARCH INSTITUTE · PI Nobuyuki Ishibashi · 2018 to 2026
$5.7M
White Matter Protection in the Fetus with Congenital Heart DiseaseR01HL146670 · NHLBI · CHILDREN'S RESEARCH INSTITUTE · PI ISHIBASHI, NOBUYUKI · 2020 to 2023
$3.3M
Mesenchymal Stromal Cell Delivery through Cardiopulmonary Bypass in Pediatric Cardiac SurgeryR33HL146394 · NHLBI · CHILDREN'S RESEARCH INSTITUTE · PI BOLLARD, CATHERINE M., ISHIBASHI, NOBUYUKI · 2019 to 2021
$2.6M
The developmental origins and fate of neurons in the gyrencephalic neocortexR21NS127051 · NINDS · CHILDREN'S RESEARCH INSTITUTE · PI HAYDAR, TARIK F, ISHIBASHI, NOBUYUKI · 2022 to 2023
$491k
NHLBI NIH HHS R01 HL139712NHLBI NIH HHS R01 HL146670NHLBI NIH HHS R33 HL146394NIH HHS R33HL146394NINDS NIH HHS R21 NS127051the Office of the Assistant Secretary of Defense for Health Affairs through the Peer Reviewed Medical Research Program W81XWH2010199
6 · The paper itself

Abstract

Phase 1 trials are primarily conducted to evaluate the safety and feasibility of new interventions, usually without recruiting control patients. This retrospective study aims to characterize clinical and biological outcomes in historical and contemporary cases of neonates and infants undergoing two-ventricle repair to facilitate future secondary endpoint analyses for such trials. This retrospective study included neonates/infants (ages ≤ 6 months) who underwent two-ventricle repair between 2015 and 2021 using the same criteria as our phase 1 trial (n = 199). Patients were allocated into the ventricular septal defect (n = 61), the Tetralogy of Fallot (TOF, n = 88), and the transposition of the great arteries (n = 50) groups with an additional comparison between two eras (2015-2019 vs. 2020-2021). Patient characteristics and most variables assessed were different between the three diagnostic groups indicating the importance of diagnostic matching for secondary analyses. Although the era did not alter cerebral/somatic oxygenation, ventricular function, neuroimaging findings, and complication rates, we observed improvement of inotropic and/or vasoactive-inotropic scores in all groups during the more recent era. In 2020-2021, the age and the body weight at the operation were higher, and hospital stay was shorter in the TOF group, suggesting the possible impact of the pandemic. Results also indicated that matching altered characteristics such as age at operation that may limit the temporal effects and optimize secondary analyses. Using optimal contemporary cases and historical data based on this study will assist in developing a comprehensive study design for a future efficacy/effectiveness trial.

Indexed as

Cardiac Surgical ProceduresClinical Trials, Phase I as TopicHeart Septal Defects, VentricularHeart VentriclesTetralogy of FallotTransposition of Great VesselsFemaleHumansInfantInfant, NewbornMaleRetrospective StudiesTreatment OutcomeCHDClinical trialPatient outcome assessmentPostoperative score

Identifiers

PMID38918239
PMCPMC11668907

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.